These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 16983521)

  • 1. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany.
    Greiner W; Lehmann K; Earnshaw S; Bug C; Sabatowski R
    Eur J Health Econ; 2006 Dec; 7(4):290-6. PubMed ID: 16983521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of strong opioids focussing on the long-term effects of opioid-related fractures: a model approach.
    Hass B; Lungershausen J; Hertel N; Poulsen Nautrup B; Kotowa W; Liedgens H
    Eur J Health Econ; 2009 Jul; 10(3):309-21. PubMed ID: 19101743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cost-effective analysis of rotation from sustained-release morphine tablet to transdermal fentanyl of matrix type or sustained-release oxycodone tablet].
    Ise Y; Wako T; Miura Y; Katayama S; Shimizu H
    Gan To Kagaku Ryoho; 2009 Dec; 36(13):2599-603. PubMed ID: 20009462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
    Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
    Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone.
    Ward A; Bozkaya D; Fleischmann J; Dubois D; Sabatowski R; Caro JJ
    Curr Med Res Opin; 2007 Oct; 23(10):2333-45. PubMed ID: 17697453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
    Sittl R; Likar R; Nautrup BP
    Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study.
    Sittl R; Nuijten M; Nautrup BP
    Clin Ther; 2005 Jul; 27(7):1022-31. PubMed ID: 16154481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy switching in patients receiving long-acting opioids.
    Berger A; Hoffman DL; Goodman S; Delea TE; Seifeldin R; Oster G
    Ann Pharmacother; 2004 Mar; 38(3):389-95. PubMed ID: 14742831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain.
    Clark AJ; Ahmedzai SH; Allan LG; Camacho F; Horbay GL; Richarz U; Simpson K
    Curr Med Res Opin; 2004 Sep; 20(9):1419-28. PubMed ID: 15383190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of tapentadol in severe chronic pain in Spain: a cost analysis of data from RCTs.
    Obradovic M; Ikenberg R; Hertel N; Antoñanzas F; Gálvez R; Liedgens H
    Clin Ther; 2012 Apr; 34(4):926-43. PubMed ID: 22417717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toward evidence-based prescribing at end of life: a comparative analysis of sustained-release morphine, oxycodone, and transdermal fentanyl, with pain, constipation, and caregiver interaction outcomes in hospice patients.
    Weschules DJ; Bain KT; Reifsnyder J; McMath JA; Kupperman DE; Gallagher RM; Hauck WW; Knowlton CH
    Pain Med; 2006; 7(4):320-9. PubMed ID: 16898943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Durogesic) with controlled-release morphine.
    Radbruch L; Lehmann K; Gockel HH; Neighbors D; Nuyts G
    Eur J Health Econ; 2002 Jun; 3(2):111-9. PubMed ID: 24577592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain.
    Payne R
    Semin Oncol; 1998 Jun; 25(3 Suppl 7):47-53. PubMed ID: 9671331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do patients prefer transdermal fentanyl or sustained-release oral morphine for treatment of chronic non-cancer pain?
    Heidemann AJ; Seaton TL
    J Fam Pract; 2001 Oct; 50(10):897. PubMed ID: 11674896
    [No Abstract]   [Full Text] [Related]  

  • 16. Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release among patients with chronic nonmalignant pain.
    Ackerman SJ; Mordin M; Reblando J; Xu X; Schein J; Vallow S; Brennan M
    J Manag Care Pharm; 2003; 9(3):223-31. PubMed ID: 14613465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.
    Wirz S; Wittmann M; Schenk M; Schroeck A; Schaefer N; Mueller M; Standop J; Kloecker N; Nadstawek J
    Eur J Pain; 2009 Aug; 13(7):737-43. PubMed ID: 18977159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the resources used in advanced cancer care between two different strong opioids: an analysis of naturalistic practice in the UK.
    Guest JF; Ruiz FJ; Russ J; Gupta RD; Mihai A; Greener M
    Curr Med Res Opin; 2005 Feb; 21(2):271-80. PubMed ID: 15801998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain.
    Neighbors DM; Bell TJ; Wilson J; Dodd SL
    J Pain Symptom Manage; 2001 Feb; 21(2):129-43. PubMed ID: 11226764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calculating the cost for drug treatment including the adverse drug reactions treatment cost (primer for fentanyl TTS in Bulgaria).
    Petrova GI; Getov IN
    Boll Chim Farm; 2002; 141(2):150-3. PubMed ID: 12135164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.